Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 1,738 trials

Lung Cancer: Zipalertinib Study

We are testing Zipalertinib in patients with advanced non-small cell lung cancer who have specific genetic mutations. The goal is to see if it is safe and effective in treating their condition.

Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Ectopic Pregnancy: Mifepristone and Letrozole vs. Methotrexate

We are studying whether a new combination treatment is as effective as the standard medication for ectopic pregnancy. This trial will also look at side effects and the need for further medical interventions.

Ectopic Pregnancy>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and Obstetrics

Progressive Glioblastoma: Perampanel Treatment Study

We are studying whether the medication Perampanel can help reduce tumor growth in patients with progressive glioblastoma before surgery. This trial also looks at quality of life and cognitive function to see how the treatment affects patients.

Progressive Glioblastoma>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyOncology

Graft-versus-Host Disease: MC0518 Treatment for Kids

We are studying a new treatment called MC0518 for children with steroid-refractory acute graft-versus-host disease after stem cell transplant. The goal is to see if it works better than the best available therapy.

Steroid Refractory Acute Graft Versus Host Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

Nitroglycerin for Esophageal Food Impaction

We are studying whether nitroglycerin can help relieve food impaction in the esophagus. This trial aims to see if it is an effective treatment for those who have trouble swallowing.

Esophageal Food Impaction>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyOtolaryngology

Growth Hormone Deficiency: LUM-201 Treatment Study

We are monitoring the long-term safety of LUM-201 in children with idiopathic growth hormone deficiency. This study also looks at how the treatment affects growth and related health markers.

Idiopathic Growth Hormone Deficiency>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Breast Cancer Surgery: ICG Imaging Study

We are exploring how a special imaging technique using ICG dye can help surgeons evaluate cancer margins during breast-conserving surgery. This study aims to find the best timing and dose for the dye to improve surgical outcomes.

Early Invasive Breast Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesGynecology and ObstetricsOncology

Dapagliflozin for Heart Health in Amyloid Transthyretin Cardiac Amyloidosis

We are studying how dapagliflozin may improve exercise capacity and quality of life for patients with ATTR-CA. This trial will also look at its safety and other health markers.

Cardiac Amyloidosis1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyInternal Medicine

Chronic Lymphocytic Leukemia: Tailored Ibrutinib Treatment

We are studying how personalized dosing of ibrutinib can improve treatment for patients with previously untreated chronic lymphocytic leukemia. The goal is to see if adjusting the dose based on side effects leads to better outcomes.

Chronic Lymphocytic Leukemia (CLL)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

LiBRA: Lithium for Cognitive Protection After Brain Radiotherapy

We are studying whether lithium can help prevent cognitive problems in children who received brain radiotherapy for cancer. The trial also looks at overall quality of life and safety of the treatment.

Brain Tumor3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyOncology

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

HER2-Negative Breast Cancer: Pembrolizumab and Radiation Therapy

We are studying a new treatment combining immunotherapy and radiation for patients with HER2-negative breast cancer who haven't responded to initial chemotherapy. The goal is to see if this approach improves cancer response and quality of life.

HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)Standard MedicinesOncology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Advanced Ovarian Cancer: Comparing Treatment Combinations

We are studying two different drug combinations to see which one helps patients with advanced ovarian cancer live longer without disease progression after surgery. This trial involves patients who have undergone complete initial surgery.

Advanced Ovarian Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Metastatic Melanoma: Diclofenac with PD-1 Inhibitor

We are studying whether adding diclofenac to ongoing PD-1 inhibitor therapy helps patients with metastatic melanoma who have stable disease. This trial aims to evaluate the potential benefits of this combination treatment.

Metastatic Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesDermatologyOncology

Advanced Solid Tumors: T3P-Y058-739 Treatment

We are testing a new genetically-modified bacterium for patients with advanced solid tumors. This study aims to explore its safety and potential benefits in treating cancer.

Solid Tumors1-2 yearsSafety phase (I)Efficacy phase (II)Oncology

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology